Neutral Biocon; target of Rs 360: Motilal Oswal

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Motilal Oswal's research report on Biocon

We recently met with BIOS’ management to understand its business outlook in greater detail. Here are the key takeaways: After two years (FY20/FY21) of earnings decline, BIOS is well-positioned to revive earnings growth meaningfully. In addition to steady traction in already launched Biosimilars, BIOS has Insulin Glargine (Semglee) contracts starting 4QFY22. This would be further supported by b-Aspart, subject to regulatory clearance. The recent agreement with the Serum Institute of India (SII) to market its COVID-19 vaccine further increases its business prospects from 2HFY23E onwards. We expect 36% earnings CAGR over FY21-23E, led by Insulin Glargine, scaling up of the Biologics business in emerging markets, and ramp-up in research services. We are yet to factor in the Vaccine business in our estimates. While the earnings outlook remains promising, we maintain our Neutral stance with a TP of INR360 per share (32x 12-month forward earnings) as current valuations factor in an earnings upside over the medium term.

Outlook

We value BIOS at 32x 12-month forward earnings to arrive at our TP of INR360. We maintain our Neutral rating as current valuations adequately captures in potential upsides from a ramp-up in launched Biosimilars in the US.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More